Anti-VEGF protein compositions and methods for producing the same

Patent metadata

Field	Value
Publication number	US-11649273-B2
Application number	US-202217575585-A
Country	US
Kind code	B2
Filing date	Jan 13, 2022
Priority date	Dec 6, 2019
Publication date	May 16, 2023
Grant date	May 16, 2023

Abstract

The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions.

First claim

What is claimed is:

1. A method of producing aflibercept, comprising:
a) producing a clarified harvest of cells cultured in a chemically defined medium (CDM);
b) binding aflibercept from said clarified harvest to an affinity chromatography column comprising a polypeptide capable of binding to or interacting with said aflibercept, wherein said polypeptide is an antibody, a fusion protein, a ScFv or a fragment thereof;
c) eluting said aflibercept of step (b) forming an affinity eluate, wherein said eluate has a first color;
d) subjecting said eluate comprising aflibercept of step (c) to anion exchange chromatography (AEX); and
e) collecting a flowthrough fraction, wherein the flowthrough fraction comprises said aflibercept, and wherein said flowthrough fraction has a second color, wherein the first color is more yellow brown than the second color.

2. The method of claim 1 , wherein said cell is selected from a group consisting of CHO, NS0, Sp2/0, embryonic kidney cells and BHK.

3. The method of claim 1 , wherein said clarified harvest includes an oxidized amino acid residue selected from the group consisting of methionine, tryptophan, histidine, phenylalanine, tyrosine and a combination thereof.

4. The method of claim 3 , wherein said oxidized amino acid residue is histidine.

5. The method of claim 3 , wherein said oxidized amino acid residue is tryptophan.

6. The method of claim 1 , wherein said clarified harvest includes an aflibercept variant selected from an amino acid residue on a polypeptide having an amino acid sequence as set forth in the group consisting of: SEQ ID NO.: 17, SEQ ID NO.: 18, SEQ ID NO.: 19, SEQ ID NO.: 20, SEQ ID NO.: 21, SEQ ID NO.: 22, SEQ ID NO.: 23, SEQ ID NO.: 56, SEQ ID NO.: 62, SEQ ID NO.: 63, SEQ ID NO.: 64, SEQ ID NO.: 65, SEQ ID NO.: 66, SEQ ID NO.: 67, SEQ ID NO.: 68, SEQ ID NO.: 69, SEQ ID NO.: 70, SEQ ID NO.: 71 and combinations thereof.

7. The method of claim 1 , wherein said AEX column comprises an anionic exchange substituent including diethylaminoethyl (DEAE), quaternary aminoethyl (QAE) and quaternary amine (Q) groups.

8. The method of claim 1 , further comprising subjecting said aflibercept of step (c) to one or more further chromatographic steps selected from the group consisting of: cation exchange chromatography, hydrophobic interactive chromatography, size exclusion chromatography and a combination thereof.

9. The method of claim 1 , wherein said eluate comprises acidic species of aflibercept and wherein said acidic species of aflibercept correspond to peaks that elute earlier than a main peak in a cation exchange chromatography (CEX) chromatogram of aflibercept, and wherein said chromatogram is generated using a first mobile phase of 20 mM 2-(N-morpholino)ethanesulfonic acid (MES), pH 5.7 and a second mobile phase of 40 mM sodium phosphate, 100 mM sodium chloride pH 9.0 (Mobile phase B), and wherein said chromatogram is generated using detection at 280 nm.

10. The method of claim 9 , wherein said percent of acidic species of aflibercept in said affinity eluate is greater than said percent of acidic species of aflibercept in said one or more flowthrough fractions when said concentrations of protein in said eluate and flowthrough fractions are normalized.

11. The method of claim 10 , wherein said acidic species of aflibercept in said affinity eluate are reduced by at least ten percent compared to said flowthrough fraction when said concentrations of said affinity eluate and flowthrough protein are normalized.

12. The method of claim 10 , wherein said aflibercept from said one or more flowthrough fractions comprises less than 20% total acidic species of aflibercept.

13. The method of claim 10 , wherein said acidic species of aflibercept comprises aflibercept having at least one oxidized amino acid residue selected from group consisting of methionine, tryptophan, histidine, phenylalanine, tyrosine and a combination thereof.

14. The method of claim 1 , wherein said AEX column is equilibrated using an equilibration buffer and washed using a wash buffer and wherein pH of both said equilibration and wash buffers is about 8.30 to about 8.60.

15. The method of claim 1 , wherein said AEX column is equilibrated using an equilibration buffer and washed using a wash buffer and wherein said conductivity of both said equilibration and wash buffers is about 1.50 to about 3.0 mS/cm.

16. The method of claim 1 , wherein said eluate comprises oxidized species of aflibercept and wherein said oxidized species of aflibercept is measured by subjecting said affinity eluate and said flowthrough fractions to digestion, followed by their analysis using reverse-phase ultra-performance chromatography (UPLC), detection at wavelengths of 280 nm, 320 nm and 350 nm and mass spectrometry analysis using said first mobile phase of 0.1% formic acid in water and a second mobile phase of was 0.1% formic acid in acetonitrile.

17. The method of claim 16 , wherein said percent of oxidized species of aflibercept in said affinity eluate is greater than said percent of oxidized species of aflibercept in said flowthrough fraction.

18. The method of claim 17 , wherein said percent of oxidized species of aflibercept in said flowthrough fraction are reduced by at least about 10% compared to said percent of oxidized species of aflibercept in said affinity eluate.

19. The method of claim 17 , wherein said oxidized amino acid residue is selected from the group consisting of methionine, tryptophan, histidine, phenylalanine, tyrosine and a combination thereof.

20. The method of claim 17 , wherein said oxidized species of aflibercept has an amino acid residue which is selected from an amino acid residue on a polypeptide having an amino acid sequence as set forth in the group consisting of: SEQ ID NO.: 17, SEQ ID NO.: 18, SEQ ID NO.: 19, SEQ ID NO.: 20, SEQ ID NO.: 21, SEQ ID NO.: 22, SEQ ID NO.: 23, and SEQ ID NO.: 67.

21. The method of claim 17 , wherein said protein further comprises one or more variant amino acid residues selected from a polypeptide having an amino acid sequence as set forth in the group consisting of: SEQ ID NO.: 17, SEQ ID NO.: 18, SEQ ID NO.: 19, SEQ ID NO.: 20, SEQ ID NO.: 21, SEQ ID NO.: 22, SEQ ID NO.: 23, SEQ ID NO.: 56, SEQ ID NO.: 64, SEQ ID NO.: 65, SEQ ID NO.: 66, SEQ ID NO.: 67, SEQ ID NO.: 68, SEQ ID NO.: 69, SEQ ID NO.: 70, SEQ ID NO.: 71, and combinations thereof.

22. The method of claim 1 , wherein said polypeptide capable of binding to or interacting with said aflibercept comprises an isolated amino acid sequence selected from a SEQ ID NO.: 72, SEQ ID NO.: 73, SEQ ID NO.: 74, SEQ ID NO.: 75, SEQ ID NO.: 76, SEQ ID NO.: 77, SEQ ID NO.: 78, SEQ ID NO.: 79 and SEQ ID NO.: 80.

23. The method of claim 1 , further comprising equilibrating said affinity chromatography column of (b) using an equilibration buffer.

24. The method of claim 23 , wherein said equilibration buffer is Dulbecco's Phosphate-Buffered Saline or Tris hydrochloride.

25. The method of claim 24 , wherein said equilibration buffer has a pH of about 8.3 to about 8.6.

26. The method of claim 1 , further comprising washing column (d) with an equilibration buffer to obtain one or more flowthrough fractions.

27. The method of claim 1 , further comprising neutralizing said eluted fractions with addition of a neutralizing buffer.

28. The method of claim 1 , wherein an amount of host-cell p

Assignees

• Regeneron Pharma

Inventors

• Tustian Andrew
• Vartak Ankit
• Daly Thomas
• Pyles Erica
• Palackal Nisha

Classifications

• C12N2529/10

  Stimulation by light · CPC title

• C12N15/85

  for animal cells · CPC title

• C07K1/06

  using protecting groups or activating agents {(C07K1/003, C07K1/006 take precedence)} · CPC title

• C12N2510/02

  Cells for production · CPC title

• C07K1/165

  mixed-mode chromatography · CPC title